Management of hypertensive crisis: British and Irish Hypertension Society Position document.

Patients with hypertensive emergencies, malignant hypertension and acute severe hypertension are managed heterogeneously in clinical practice. Initiating anti-hypertensive therapy and setting BP goal in acute settings requires important considerations which differ slightly across various diagnoses and clinical contexts. This position paper by British and Irish Hypertension Society, aims to provide clinicians a framework for diagnosing, evaluating, and managing patients with hypertensive crisis, based on the critical appraisal of available evidence and expert opinion.

Higher cigarette prices influence cigarette purchase patterns.

OBJECTIVE: To examine cigarette purchasing patterns of current smokers and to determine the effects of cigarette price on use of cheaper sources, discount/generic cigarettes, and coupons. BACKGROUND: Higher cigarette prices result in decreased cigarette consumption, but price sensitive smokers may seek lower priced or tax-free cigarette sources, especially if they are readily available. This price avoidance behaviour costs states excise tax money and dampens the health impact of higher cigarette prices. METHODS: Telephone survey data from 3602 US smokers who were originally in the COMMIT (community intervention trial for smoking cessation) study were analysed to assess cigarette purchase patterns, use of discount/generic cigarettes, and use of coupons. RESULTS: 59% reported engaging in a high price avoidance strategy, including 34% who regularly purchase from a low or untaxed venue, 28% who smoke a discount/generic cigarette brand, and 18% who report using cigarette coupons more frequently that they did five years ago. The report of engaging in a price avoidance strategy was associated with living within 40 miles of a state or Indian reservation with lower cigarette excise taxes, higher average cigarette consumption, white, non-Hispanic race/ethnicity, and female sex. CONCLUSION: Data from this study indicate that most smokers are price sensitive and seek out measures to purchase less expensive cigarettes, which may decrease future cessation efforts.

Marrow aplasia following topical application of chloramphenicol eye ointment.

Chloramphenicol-induced aplastic anemia is well described in the literature following oral use of the drug. Here we describe the first case we are aware of in which chloramphenicol eye ointment resulted in severe aplastic anemia and, subsequently, death. At least two cases of marrow hypoplasia following use of chloramphenicol eyedrops have been described previously in the literature. The absorption route, its possible relation to the pathogenesis of aplastic anemia, and the two types of marrow toxicity associated with chloramphenicol are reviewed. This case emphasizes the necessity for the same careful consideration for the use of topical preparations that one affords the use of parenterally and orally administered medications.

Early therapy of renal bone disease with calcitriol: a prospective double-blind study.

The value of calcitriol administration in the management and prevention of renal bone disease was studied in a prospective double-blind manner in 16 patients with chronic renal impairment (creatinine clearance 20 to 59 ml per min). They were given either calcitriol at a dose of 0.25 to 0.5 micrograms daily (eight patients), or placebo. Transiliac crest bone biopsies were performed before entrance into the study and after 12 months of experimental observation. None of the patients were symptomatic or had biochemical or radiological evidence of bone disease. Of the thirteen patients who completed the study, initial serum 1,25(OH)2D levels were low in seven patients and parathyroid hormone levels were elevated in seven patients. Bone histology was abnormal in all patients. Calcitriol treatment was associated with a significant fall in serum phosphorus concentrations and alkaline phosphatase levels as well as with histological evidence of an amelioration of hyperparathyroid changes. In contrast to previous reports, no deterioration of renal function attributable to the treatment occurred, perhaps because a modest dose of calcitriol was employed combined with meticulous monitoring. Further investigation is required to determine whether alternative therapeutic strategies (smaller doses or intermittent therapy) may avoid the potential for suppressing bone turnover to abnormally low levels in the long term.

Controlled trial of calcitriol in hemodialysis patients.

We report on a 5-year, prospective, double-blind trial of 1,25 dihydroxycholecalciferol (calcitriol) versus placebo in 76 hemodialysis patients without biochemical or radiological evidence of bone disease. Calcitriol, 1 microgram daily, regularly induced hypercalcemia. Doses of 0.25 microgram daily or less proved satisfactory in most patients. During calcitriol treatment, plasma calcium concentration was significantly higher and serum parathyroid hormone concentration significantly lower than on placebo. There was no difference in the rates of development or of progression of vascular calcification in the two groups. Significantly more patients on placebo (17 vs. 6, p less than 0.05) developed a sustained elevation of plasma alkaline phosphatase concentration. Calcitriol appeared to protect against the development of histological evidence of osteitis fibrosa but not of osteomalacia, but accumulation of aluminum in bone occurred during the study. We conclude that calcitriol delays and may prevent the development of osteitis fibrosa in patients receiving regular hemodialysis and may reasonably be prescribed routinely in hemodialysis patients without biochemical or radiological abnormality, unless there is a substantial prospect of early renal transplantation.

Protein binding of indomethacin, methotrexate and morphine in patients with cancer.

The in vitro protein binding of indomethacin, morphine and methotrexate has been studied in two groups of ten patients each suffering from different types of cancers and compared with twenty normal adult subjects. One group of patients had active disease and the other group was in complete clinical remission. Serum samples were obtained from each subject and the concentrations of albumin and alpha-1 acid glycoprotein (AGP) were measured. Protein binding of drugs was determined using equilibrium dialysis. Alpha-1 acid glycoprotein levels were increased in patients and this effect was more pronounced in active disease (1802 +/- 1025 mg/l) than in remission (931 +/- 273 mg/l). Albumin levels were reduced in active disease (47.67 +/- 15.91 milligrams), but not in remission (61.86 +/- 6.62 milligrams), as compared to control values (58.98 +/- 9.9 milligrams). The protein binding of methotrexate and indomethacin were both reduced in active disease (34.17 +/- 7.12% and 96.26 +/- 0.93% respectively) in comparison with normal subjects (39.33 +/- 4.68% and 96.89 +/- 0.47% respectively), but that of morphine was not changed. In patients there was a strong negative correlation between albumin and alpha-1 acid glycoprotein levels (r = -0.75, p < 0.01) but the correlation in controls was not significant. This study found only weak association between the binding of the drugs studied and the protein levels. It is concluded that reduction in methotrexate dose levels may reduce toxicity in patients with active cancer.

Effect of hay substitution on intake and digestibility of forage rape (brassica napus) fed to lambs.

Intake and digestibility trials were conducted with sheep to evaluate the effect of adding various levels of a typical fibrous grass forage (neutral detergent fiber, NDF = 68%) to a high quality, low fiber (NDF = 22%) brassica forage. Four forage rape:orchardgrass hay diets (0, 40, 70, 100% rape content on a dry matter basis) were fed to groups of six Polled-Dorset crossbred growing wether lambs (39.6 kg) individually housed in metabolism crates. After a 7-d ad libitum intake period, a 7-d digestibility trial was conducted at 90% of the observed ad libitum intake level. Digestible dry matter intake (DDMI) per unit metabolic body weight increased as rape in the diet was increased from 0 to 70%, with increases in both dry matter intake and dry matter digestibility (DMD). However, DDMI was similar for lambs fed the 70 and 100% rape diets, with DMI decreasing to the same relative extent as DMD increased. Digestibility of the cell wall fraction of the two intermediate diets (40% rape and 70% rape) was lower than predicted from component forage digestibilities. This observation suggests the existence of an associative effect similar to that often reported when forage and concentrates are fed in various ratios. Forage brassicas appear to be utilized in the ruminant in a manner more typically resembling a concentrate than a forage.

Indomethacin and protein binding of methotrexate.

Indomethacin, a non-steroidal anti-inflammatory drug is known to increase the efficacy and toxicity of methotrexate, the widely used anti-cancer drug in man. The mechanism for this interaction has not been clearly established. However, since these drugs bind with albumin, a possible displacement of methotrexate by indomethacin from albumin might explain this interaction. To investigate the possible interaction an in-vitro protein-binding displacement study was carried out in 17 normal volunteers and in two groups of eight cancer patients. One group of patients had active disease and the other was in complete clinical remission. Serum samples were obtained and protein levels estimated. The protein binding of methotrexate was measured alone and with indomethacin using equilibrium dialysis. Statistical analysis of results suggested that the binding of methotrexate is not influenced by indomethacin, confirming that methotrexate is not displaced by indomethacin.

Association of fake-good MMPI-2 profiles with low Beck Depression Inventory scores.

Seventy-nine adolescent mothers (mean age = 18.1 years) were administered the Beck Depression Inventory (BDI) and three validity scales (L, F, and K) of the Minnesota Multiphasic Personality Inventory 2 (MMPI-2). The aim was to determine whether low-BDI mothers were "faking good," or denying their depression. The adolescent mothers were assigned to a low-BDI group (scores = 0, 1, 2), a nondepressed group (scores = 3-9), or a depressed group (scores > or = 13). The depressed group had higher F (Symptom) scale scores than did the nondepressed group, which in turn had higher scores than did the low-BDI group. The low-BDI group, in contrast, had more fake-good profiles than did the two other groups. Discriminant analyses indicated that 90% of the fake-good profiles could be classified correctly based on BDI and K (Defensiveness) scale scores. These data suggest the need for further assessment when individuals have extremely low BDI scores.

The role of alpha-adrenoceptor blockade in the treatment of hypertension.

Early attempts to use alpha-adrenoceptor blockers in the treatment of hypertension were unsuccessful due to a high prevalence of side-effects. Now that the concept of two alpha-adrenoceptors, alpha 1 and alpha 2 has been investigated, specific alpha 1 postsynaptic adrenoceptor blocking drugs have become available to treat hypertension. Their efficacy, tolerance and acceptability are discussed, and indications for their usage suggested.

Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects.

We have studied the pharmacokinetics and absolute systemic availability of indoramin (50 mg) given orally in solution or as a tablet with reference to intravenously administered drug (0.15 mg/kg) in 9 healthy volunteers. After intravenous administration the median apparent volume of distribution was 6.3 l X kg-1, plasma clearance was 20.0 ml X min-1 X kg-1, and terminal half-time was 4.1 h. When given by tablet indoramin was absorbed with moderate rapidity, with a median tmax of 1.5 h. The median systemic availability was 24%. After oral administration in solution the drug was more rapidly absorbed, with a median tmax of 1.0 h (p less than 0.01). The median systemic availability was 43% (15-85%). Plasma concentrations of an active metabolite, 6-hydroxyindoramin, after single oral doses in either dosage form, were of a similar order to those of unchanged drug and fell with similar rapidity. After intravenous administration, however, concentrations of the metabolite were negligible.

Anticholinergic drugs, buccal ulceration and mucosal potential difference.

Measurement of changes in buccal mucosal potential difference produced by contact with drug formulations may provide a means of predicting their mucosal toxicity and ulcerogenic activity.

Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite.

Intra- and inter-subject variation in the kinetics of indoramin and its active metabolite 6-hydroxyindoramin have been studied in 5 young, healthy, male volunteers administered a single oral dose of the drug on 5 separate occasions. Inter-subject variation represented the main source of variability in indoramin plasma concentrations with, for example, the between-subjects sum of squares (a measure of the contribution to the total variability) representing around 97% of the total sum of squares for Cmax and AUC (0-24). Intra-subject and inter-subject coefficients of variation (C.V.s) were circa 20% and 100% respectively for both these parameters. Variability in 6-hydroxyindoramin concentrations was much lower and was approximately equally derived from intra- and inter-subject variation, with the C.V.s being approximately 44% for both Cmax and AUC (0-24). The results imply that the kinetic behaviour of indoramin within an individual will prove relatively consistent, despite widespread inter-subject variation, once an appropriate dosage regime has been established.

Ruminal in vitro degradability of protein in alfalfa harvested as standing forage or baled hay.

Eighty-nine samples, 45 of standing forage and 44 of baled hay, were collected from alfalfa harvested at various maturities over three cuttings each during 2 yr. Alfalfa was cut and conditioned mechanically; samples of standing forage were collected by removing bunches of forage from windrows and freeze-drying them. Forage was allowed to field cure and was harvested at an average 80% DM as small rectangular bales; samples of baled hay were collected by coring bales after storing for 3 to 6 mo. Samples were analyzed for DM, ADF, total N, fractions of total N present as ADIN, N degraded at 0 h, and potentially degradable protein N. Ruminal protein degradation rates and escapes were estimated using an inhibitor in vitro system, assuming that ADIN was unavailable and that ruminal passage rate was .06/h. Standing forage contained smaller fractions of ADIN and N degraded at 0 h, contained a larger fraction of potentially degradable N, and had more rapid degradation rates and lower estimated protein escapes than baled hay. Mean degradation rates and estimated escapes were .171/h and 24% for standing forage and .075/h and 40% for baled hay. There were no differences in degradation rate or estimated escape because of harvest year, and neither was significantly related to maturity or to ADF concentration. Results indicate a significant advantage in ruminal protein escape, compared with grazed alfalfa, for alfalfa harvested and stored as hay.

Addition of buffers to high quality alfalfa hay-based diets for dairy cows in early lactation.

Beginning 4 wk postpartum, 14 Holstein cows were paired according to expected calving date and lactation number and assigned randomly to one of two treatments in a single reversal experiment designed to study the effects of added buffers to high quality alfalfa hay-based diets. Cows were offered daily 14.5 kg of concentrate containing 0 or 2% sodium bicarbonate and .5% magnesium oxide (as fed), plus free choice high quality alfalfa hay in a ratio of forage:grain approaching 50:50 (dry matter). No differences were in milk production, milk fat percentage, fat-corrected milk, or dry matter intake. Dry matter intake of grain was decreased with addition of buffers. Kilograms fat-corrected milk per kilogram of dry matter intake were 1.41 and 1.45 for control and buffered diets. No differences were significant for rumen pH, ammonia concentration, molar proportions of acetate and propionate, or ratio of acetate: propionate. Concentrations of total volatile fatty acids were higher for cows fed the buffered diet. No differences were in blood acid-base status or in various serum metabolites. Urine pH was 8.11 and 8.20 for control and buffered diets. Fractional urinary excretion of magnesium and sodium was greater when cows consumed the buffered diet. Diet digestibilities and rate of passage were not affected by dietary buffers. Addition of sodium bicarbonate plus magnesium oxide did not improve performance of early lactation cows fed high quality alfalfa hay as the sole forage.

Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.

Marked interindividual variation has been observed in the pharmacokinetics of the antiarrhythmic agent mexiletine. The fact that its urinary excretion is dependent on urinary pH may account, in part, for such variation. The influence that genetic differences in hepatic metabolism of the debrisoquine-type may have on mexiletine pharmacokinetics was considered in this study. The pharmacokinetics and urinary excretion of mexiletine (250 mg administered intravenously) were investigated in 5 rapid extensive metabolisers (EM), 5 slow EM and 5 poor metabolisers (PM) of debrisoquine, under conditions of controlled urinary pH. Mexiletine disposition kinetics was found to be altered in PM individuals. These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1). In this respect, slow EM individuals generally presented intermediate values of those pharmacokinetic parameters. A higher incidence of adverse-effects was also observed among slow EM and PM subjects. It is concluded that genetic differences in mexiletine oxidation of the debrisoquine-type have an influence on its observed pharmacokinetic variability. The clinical consequences are discussed.

Circadian variation in theophylline absorption during chronic dosing with a slow release theophylline preparation and the effect of clock time of dosing.

1. Eight volunteers were given seven doses of 200 mg of slow release theophylline at either 11.00 h and 23.00 h (regimen 1) or 17.00 h and 05.00 h (regimen 2). At the time of the sixth dose (60 h) hourly blood sampling was started and continued for 24 h. After at least 1 week volunteers crossed over to the other regimen. 2. Volunteers retired to bed at 23.00 h and arose after the 07.00 h sample during both regimens. 3. During regimen 1 there was a marked rise in mean tmax from 3.3 h after dosing at 11.00 h to 9.3 h after dosing at 23.00 h (P less than 0.001). There was also a fall in AUC(0,12) from 89.9 mg l-1 h after dosing at 11.00 h to 79.0 mg l-1 h after dosing at 23.00 h. There was no difference in mean Cmax values. 4. During regimen 2 these circadian changes were abolished with mean values after both dosing times lying between those observed during regimen 1. 5. A marked delay in absorption occurs at night and cannot be explained by food intake.

Use of a standard forage to reduce effects of animal variation on estimates of mean voluntary intake.

Sixty test forages (alfalfa, timothy, bromegrass, and orchardgrass mixtures), of differing cuttings and maturities, were harvested as hay in each of 2 yr (30/yr) from three locations. Each of the 60 hays was chopped and fed to four growing sheep to determine voluntary intake. The duration of the trial was 2 yr with five experimental periods per year. In each period, immediately prior to feeding the test forages, intake of the same standard alfalfa hay (standard forage) was measured for every sheep. Use of intake of the standard forage as a covariate reduced mean square error by 38%. Regression of least squares means of intake of the test forages on chemical composition uniformly yielded higher coefficients of determination when means were generated from an analysis of variance that included intake of the standard forage as a covariate. This procedure can be used to increase the accuracy of estimates of mean voluntary intake or to reduce the number of animals needed to attain the same accuracy that would be achieved without use of the covariate.

The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers.

Eight healthy volunteers received slow release nifedipine 20 mg 12 hourly, for six doses. A nifedipine pharmacokinetic profile was performed after the fifth dosing interval using 12 sampling times over 12 h. A specific high pressure liquid chromatography (h.p.l.c.) nifedipine assay was used. Six of the volunteers subsequently received an i.v. infusion of 3.5 mg of nifedipine after an identical period (five dosing intervals) of chronic oral dosing with slow release nifedipine 20 mg 12 hourly. An identical pharmacokinetic profile was performed after the infusion. Bioavailability, clearance (CL), apparent volume of distribution (V), apparent half life (t1/2) and area under the curve (AUC) were calculated. The geometric mean apparent t1/2 for the slow release preparation was 6.3 +/- 2.0 h. In the six volunteers, the mean bioavailability was 46% (range 29-86%), the mean CL was 588.0 +/- 67.1 ml min-1, the mean apparent V was 160.1 +/- 61.7 l. The pharmacokinetics of slow release nifedipine during chronic dosing appear similar to those derived from single dose studies.

Pharmacokinetic interaction between indoramin and ethanol.

1. The effect of ethanol consumption (0.5 g/kg) on the pharmacokinetics of the alpha adrenoceptor antagonist indoramin, administered orally (50 mg) or intravenously (0.175 mg/kg) has been investigated in young volunteers. Sedation was also assessed using a visual analogue scale. 2. After oral indoramin administration, ethanol caused increases of 58% (P less than 0.01) in Cpmax, and 25% (P less than 0.05) in AUC. There was no effect of alcohol on elimination half-life. The combination of ethanol and indoramin was more sedative than indoramin alone. 3. Ethanol did not alter the pharmacokinetics of an intravenous dose of indoramin. However indoramin caused a small but statistically significant increase (26%) in blood ethanol concentrations during the first 1.25 h after dosing. Both indoramin and ethanol caused sedation. 4. The increased bioavailability of oral indoramin in the presence of ethanol may reflect some enhanced absorption, but it is also consistent with inhibition of first-pass metabolism of a flow-limited drug. The clinical implications are discussed.